Research programme: estradiol dehydrogenase inhibitors - Forendo Pharma

Drug Profile

Research programme: estradiol dehydrogenase inhibitors - Forendo Pharma

Alternative Names: 17-beta hydroxysteroid dehydrogenase inhibitors; 17-β HSD type-1 inhibitors; 17β-HSD1 inhibitors; Estradiol dehydrogenase inhibitors; HSD inhibitors programme; HSD programme; HSD-1

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hormos Medical; Solvay Pharmaceuticals; University of Turku
  • Developer Abbott Laboratories; QuatRx Pharmaceuticals
  • Class
  • Mechanism of Action Estradiol dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Endometriosis; Uterine leiomyoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Endometriosis in Finland
  • 25 Jun 2013 Estradiol dehydrogenase inhibitors are still in Preclinical trials for Endometriosis in Finland
  • 25 Jun 2013 Forendo Pharma acquires estradiol dehydrogenase inhibitors programme from Hormos Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top